MW 398.4 Da, Purity >99%. Selective cell-permeable inhibitor of casein kinase 1 (CK1) . (IC50 values are 0.3 (CK1), 0.5 (ALK5), 9.1 (PKd1) and 5.8 μM (p38αMAPK)). Displays selectivity over many other protein kinases.
AAT 5, ACVRLK 4, ALK-5, Activin A receptor type II like kinase, Activin A receptor type II like kinase 53kDa, Activin A receptor type II like kinase, 53kD, Activin receptor-like kinase 5, CDC-like kinase 1, CDC28/CDC2 like kinase, CLK/STY, CLK1_HUMAN, CSAID Binding Protein 1, CSAID-binding protein, CSBP, CSBP 1, CSBP 2, CSPB1, Csaids binding protein, Cytokine suppressive anti-inflammatory drug-binding protein, Dual specificity protein kinase CLK1, EXIP, KPCD1_HUMAN, LDS1A, LDS2A, MAP kinase 14, MAP kinase MXI2, MAP kinase p38 alpha, MAPK 14, MAX-interacting protein 2, MK14_HUMAN, MSSE, Mitogen-activated protein kinase 14, Mitogen-activated protein kinase p38 alpha, Mxi 2, P38, PKC, PKC MU, PKCM, PKD, PRKCM, PRKD 1, PRKM14, PRKM15, Protein kinase C mu, Protein kinase C mu type, Protein kinase D, Protein kinase D1, Protein tyrosine kinase STY, RK, SAPK2A, SKR 4, STY, Serine/threonine-protein kinase D1, Serine/threonine-protein kinase receptor R4, Stress-activated protein kinase 2a, TGF-beta receptor type I, TGF-beta receptor type-1, TGF-beta type I receptor, TGFBR 1, TGFBR1 protein, TGFR1_HUMAN, TbetaR-I, Transforming growth factor beta receptor 1, Transforming growth factor beta receptor I, Transforming growth factor beta receptor I (activin A receptor type II like kinase, 53kD), Transforming growth factor-beta receptor type I, activin A receptor type II-like protein kinase of 53kD, nPKC-D1, nPKC-mu, p38 ALPHA, p38 MAP kinase, p38 MAPK, p38 mitogen activated protein kinase, p38alpha Exip
MW 398.4 Da, Purity >99%. Selective cell-permeable inhibitor of casein kinase 1 (CK1) . (IC50 values are 0.3 (CK1), 0.5 (ALK5), 9.1 (PKd1) and 5.8 μM (p38αMAPK)). Displays selectivity over many other protein kinases.
Soluble in DMSO to 100 mM.
Selective cell-permeable inhibitor of casein kinase 1 (CK1) . (IC50 values are 0.3 (CK1), 0.5 (ALK5), 9.1 (PKd1) and 5.8 μM (p38αMAPK)). Displays selectivity over many other protein kinases.
P38 also known as MAPK14 weighs approximately 43 kDa and is a member of the mitogen-activated protein kinase family. It is expressed in many tissues with high levels in the heart and skeletal muscle. p38 acts mechanically by phosphorylating various substrates involved in cellular responses to stress and inflammation. Protein Kinase C mu/PKD also referred to as PKD1 is part of the protein kinase D family. It has a mass of around 115 kDa and functions by relaying signaling pathways important for maintaining cellular activities. TGF beta Receptor I also known as activin receptor-like kinase 5 (ALK5) is a serine/threonine kinase of about 53 kDa found in various tissues. CLK1 or CDC-like kinase 1 has a mass of approximately 52 kDa and plays roles in pre-mRNA splicing and regulation.
All these proteins play key roles in cellular communication and response modulation. p38 adjusts the cellular response to external stress signals and inflammation and it often forms part of larger signaling complexes. PKC mu/PKD regulates signal transduction pathways involved in cell proliferation and migration. TGF beta Receptor I mediates signaling for TGF-beta regulating cell growth and differentiation. CLK1 influences aspect of RNA splicing affecting gene expression and cellular metabolism.
P38 MAPK signaling includes phosphorylation chains impacting cellular inflammatory response while closely interacting with proteins like MKK3 and MKK6. PKC mu/PKD signaling is integral to the DAG-activated pathway where it associates with proteins like Rac1. TGF beta Receptor I is critical for the TGF-beta signaling pathway interacting with SMAD proteins to transduce signals. CLK1 affects the CLK1 signaling pathway influencing RNA splicing through interactions with SR proteins.
P38 links to conditions such as inflammatory diseases and cancer. It connects with cytokine signaling proteins impacting disease progression. PKC mu/PKD associates with cancer and cardiovascular diseases through its role in cellular proliferation. TGF beta Receptor I's dysfunction correlates with fibrotic diseases through interactions with ECM-modifying proteins. CLK1 relates to neurological disorders influencing proteins involved in RNA processing such as ASF/SF2.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
2D chemical structure image of ab120220, D4476, CK1 inhibitor
ab38511 staining βcatenin (phospho Thr42 + Ser45) in SK-N-SH cells treated with D4476 (ab120220), by ICC/IF. Decrease in expression of βcatenin (phospho Thr42 + Ser45) correlates with increased concentration of D4476, as described in literature.
The cells were incubated at 37°C for 2h in media containing different concentrations of ab120220 (D4476) in DMSO, fixed with 4% formaldehyde for 10 minutes at room temperature and blocked with PBS containing 10% goat serum, 0.3 M glycine, 1% BSA and 0.1% tween for 2h at room temperature. Staining of the treated cells with ab38511 (5 μg/ml) was performed overnight at 4°C in PBS containing 1% BSA and 0.1% tween. A DyLight 488 goat anti-rabbit polyclonal antibody (Goat Anti-Rabbit IgG H&L (DyLight® 488) preadsorbed ab96899) at 1/250 dilution was used as the secondary antibody. Nuclei were counterstained with DAPI and are shown in blue.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com